GEN Exclusives

More »

GEN News Highlights

More »
Dec 20, 2007

Bavarian Nordic Achieves $25M Milestone from the HHS

  • Bavarian Nordic reports that it has reached another milestone in its agreement with the U.S. government and will thus receive $25 million. In June, the HHS contracted the firm to manufacture and deliver 20 million doses of its smallpox vaccine in a deal potentially worth $1.6 billion.

    This year, Bavarian Nordic has received $100 million in relation to this deal. The firm was reportedly paid $50 million in advance. It also received another $25 million milestone fee just three weeks ago.

    Next year, Bavarian Nordic expects to receive yet another milestone payment of $25 million.
    Imvamune is based on the Modified Vaccinia Ankara virus, a live virus but one that does not replicate in the body, according to the company.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?